NEW YORK, Sept. 21, 2015 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) shares closed at $1.13 off $.07 in Friday's session. Share volume exceeded the 30 day average by a factor of five with 532 thousand shares being traded.
Our due diligence will give investors in Soligenix the information they need. Gain insight by reading the due diligence report at the link below.
Copy and paste to browser may be required.
About Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company developing product candidates intended to address unmet medical needs in areas of inflammation, oncology, and biodefense. They have two active business segments: BioTherapeutics and Vaccines/BioDefense.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This release and report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this release have not been compensated in any form by any source. A full disclaimer can be found by viewing due diligence. We are only human and may make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.